Emerald Clinics, is to rebrand as Emyria Limited.
The company said the name change is “consistent with its global ambitions and expanded offerings”.
Shares soared almost 30% on the news, to close at $0.079. Emerald listed on the ASX earlier this year, reaching a share high of $0.14 in February.
The name change, which must be approved by shareholders at a general meeting next month, comes after Emerald signed a deal with Spectrum Biomedical UK (SBUK), the UK subsidiary of the world’s largest cannabis company Canopy Growth, to develop a Real-World Evidence system.
